Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:59:03 2024-06-21 EDT			5-day change	1st Jan Change
0.1568 ^USD	+5.63%		-1.38%	+63.33%

05-21	Provectus Biopharmaceuticals, Inc. Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting	CI
05-14	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 14, 2024 at 02:43 pm

Provectus Biopharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 0.504042 million compared to USD 0.827454 million a year ago.

Latest news about Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting	05-21	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose	04-18	CI
Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	04-16	CI
Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer	04-16	CI
Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting	04-11	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Provectus Biopharmaceuticals, Inc. Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium	03-27	CI
Provectus Biopharmaceuticals, Inc. Announces Management Changes	03-26	CI
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma	11-15	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Metastatic Uveal Melanoma	11-13	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas	23-06-28	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10(R) and Keytruda(R) for First-Line Stage III Melanoma at Melanoma Bridge 2022	22-12-01	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Provectus Biopharmaceuticals Inc. Establishes Research Collaboration with University of Texas Medical Branch At Galveston	22-09-29	CI
Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections	22-09-21	CI
Provectus Biopharmaceuticals, Inc. announced that it expects to receive $5 million in funding	22-09-19	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair	22-07-19	CI
Provectus Biopharmaceuticals Presents Data from PV-10 Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology Congress	22-06-30	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI

Chart Provectus Biopharmaceuticals, Inc.

Duration

Period

Chart Provectus Biopharmaceuticals, Inc.

More charts

Company Profile

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Companyâs lead molecule is named rose bengal sodium (RBS). The Companyâs small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Companyâs HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROVECTUS BIOPHARMACEUTICALS, INC.	+63.33%	65.76M
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-16.19%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B
INSMED INCORPORATED	+119.39%	10.96B

Bio Therapeutic Drugs